Questions to Ask at Your Screening When you disclose GLP-1 use during your screening, these questions help clarify the protocol specific to your situation and the programs requirements
For the outcomes of MACEs, major adverse liver events and gastrointestinal adverse events, we further excluded individuals with a history of these conditions before T0
Reduced reliance on medical care was seen
Effectiveness Two large trials evaluated Zepbound in individuals who were overweight or obese
Youll need to ensure that your vial, syringe, and skin are prepped and sanitized before being injected
Barnhill RL, Albert LS, Shama SK, Goldenhersh MA, Rhodes AR, Sober AJ